Cell Source Inc (CLCS) 0.9000 $CLCS
Fate Therapeutics Announces Issuance of U.S. Patent on Compositions of Human Induced Pluripotent Cells
GlobeNewswire - Tue Jul 26, 7:02AM CDT
Key Patent Covers Renewable Pluripotent Cell Source for Development of Off-the-Shelf NK- and T-Cell Immunotherapies
FATE: 1.71 (+0.03)
Cell Source Improving Immunotherapy with T-Cell Twist
ACCESSWIRE - Tue Apr 26, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / Immunotherapy is undoubtedly one of the most talked about and promising areas in biotechnology today. As the library of research continues to grow, combination therapies are emerging to hopefully deliver more clinically meaningful outcomes. This is exemplified by the recent pact between Kite Pharma (NASDAQ: KITE) and Roche's (OTCQX: RHHBY) Genentech to collaborate (http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=961129) on using Kite's experimental CAR-T (chimeric antigen-receptor T cell) treatment, KTE-C19, in combination with Roche's PD-L1 (programmed death ligand-1) immunotherapy, atezolizumab, in patients suffering from refractory, aggressive non-Hodgkin lymphoma (NHL).
KITE: 51.19 (-0.32), AMGN: 166.89 (+0.33), TEVA: 54.26 (-0.07)
Cell Source to Present at the LD Micro Main Event
Marketwired - Fri Nov 27, 8:34AM CST
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced that it will be presenting at the 8th annual LD Micro Main Event on Thursday, December 3rd at 4PM PST. Itamar Shimrat (CEO of Cell Source) will be giving the presentation and meeting with investors.
Cell Source's Megadose Drug Combination Treats First Patient
Marketwire Canada - Wed Nov 11, 7:51AM CST
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today initial indications that its Megadose Drug Combination has been used to successfully treat a cancer patient in Italy. Cell Source's proprietary Megadose Drug Combination (licensed exclusively from the Weizmann Institute of Science in Israel) is expected to increase bone marrow transplantation (BMT) success and survival.
Inaugural Scientific Advisory Board Summit JV Pharma Collaboration Initiative
Marketwired - Wed Nov 04, 8:14AM CST
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced their initiative for joint venture Pharma collaborations at their inaugural Scientific Advisory Board (SAB) Summit held in New York City. SAB members are leading experts from Harvard University, Stanford University, Oxford University, Mt. Sinai Medical and University Hospital Wurzburg. They have endorsed Cell Source's pursuit of JV collaborations with major Pharma players. Recent scientific developments and new provisional patent applications have set the stage for these JV Pharma Collaborations to leverage Cell Source's Veto Cell technology and accelerate its commercialization.
Cell Source names Dr Dennis Brown as board chairman
M2 - Thu Aug 20, 3:52AM CDT
Biotechnology company Cell Source(OTC BB:CLCS) reported on Wednesday it has appointed Dr Dennis Brown as the chairman of its board of directors.
Cell Source Appoints Dr. Dennis Brown as Chairman of Its Board of Directors
Marketwired - Wed Aug 19, 8:04AM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Dennis Brown, currently a Director of Cell Source, has been appointed Chairman of the Board of Directors.
Cell Source Appoints Dr. Robert Negrin to Its Scientific Advisory Board
Marketwired - Mon Jul 06, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Robert S. Negrin, Director of the Bone and Marrow Transplantation Division and Professor of Medicine at Stanford University, has joined its Scientific Advisory Board.
Cell Source Appoints Dr. Steven Burakoff to Its Scientific Advisory Board
Marketwired - Mon Jun 29, 7:30AM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Steven Burakoff, Director of the Tisch Cancer Institute at Mount Sinai Medical Center and Professor of Cancer Medicine and Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, has joined its Scientific Advisory Board.
World Class Immunologist Dr. Herman Waldmann Joins Cell Source's Scientific Advisory Board
Marketwired - Wed Jun 17, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Herman Waldman, who served as Department Head and Professor Emeritus of Pathology at the Oxford Medical School and Clinical Director of Oxford's Therapeutic Antibody Centre, has joined the Cell Source Scientific Advisory Board.
Cell Source names Dr Terry Strom as SAB chair
M2 - Fri Jun 05, 4:52AM CDT
Biotechnology company Cell Source (OTCBB:CLCS) revealed on Thursday the addition of Dr Terry Strom as chairman of its Scientific Advisory Board (SAB).
Cell Source Appoints Dr. Terry Strom as Chairman of Its Scientific Advisory Board
Marketwired - Thu Jun 04, 10:22AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Terry Strom, Professor of Medicine and Surgery at Harvard Medical School and Director of The Transplant Institute at Beth Israel Deaconess Medical Center, has been retained to serve as Chairman of its Scientific Advisory Board.
Fate Therapeutics Announces Issuance of U.S. Patent on Compositions of Human Induced Pluripotent Cells
GlobeNewswire - Tue Jul 26, 7:02AM CDT
Key Patent Covers Renewable Pluripotent Cell Source for Development of Off-the-Shelf NK- and T-Cell Immunotherapies
FATE: 1.71 (+0.03)
Cell Source Improving Immunotherapy with T-Cell Twist
ACCESSWIRE - Tue Apr 26, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / Immunotherapy is undoubtedly one of the most talked about and promising areas in biotechnology today. As the library of research continues to grow, combination therapies are emerging to hopefully deliver more clinically meaningful outcomes. This is exemplified by the recent pact between Kite Pharma (NASDAQ: KITE) and Roche's (OTCQX: RHHBY) Genentech to collaborate (http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=961129) on using Kite's experimental CAR-T (chimeric antigen-receptor T cell) treatment, KTE-C19, in combination with Roche's PD-L1 (programmed death ligand-1) immunotherapy, atezolizumab, in patients suffering from refractory, aggressive non-Hodgkin lymphoma (NHL).
KITE: 51.19 (-0.32), AMGN: 166.89 (+0.33), TEVA: 54.26 (-0.07)
Cell Source to Present at the LD Micro Main Event
Marketwired - Fri Nov 27, 8:34AM CST
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced that it will be presenting at the 8th annual LD Micro Main Event on Thursday, December 3rd at 4PM PST. Itamar Shimrat (CEO of Cell Source) will be giving the presentation and meeting with investors.
Cell Source's Megadose Drug Combination Treats First Patient
Marketwire Canada - Wed Nov 11, 7:51AM CST
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today initial indications that its Megadose Drug Combination has been used to successfully treat a cancer patient in Italy. Cell Source's proprietary Megadose Drug Combination (licensed exclusively from the Weizmann Institute of Science in Israel) is expected to increase bone marrow transplantation (BMT) success and survival.
Inaugural Scientific Advisory Board Summit JV Pharma Collaboration Initiative
Marketwired - Wed Nov 04, 8:14AM CST
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced their initiative for joint venture Pharma collaborations at their inaugural Scientific Advisory Board (SAB) Summit held in New York City. SAB members are leading experts from Harvard University, Stanford University, Oxford University, Mt. Sinai Medical and University Hospital Wurzburg. They have endorsed Cell Source's pursuit of JV collaborations with major Pharma players. Recent scientific developments and new provisional patent applications have set the stage for these JV Pharma Collaborations to leverage Cell Source's Veto Cell technology and accelerate its commercialization.
Cell Source names Dr Dennis Brown as board chairman
M2 - Thu Aug 20, 3:52AM CDT
Biotechnology company Cell Source(OTC BB:CLCS) reported on Wednesday it has appointed Dr Dennis Brown as the chairman of its board of directors.
Cell Source Appoints Dr. Dennis Brown as Chairman of Its Board of Directors
Marketwired - Wed Aug 19, 8:04AM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Dennis Brown, currently a Director of Cell Source, has been appointed Chairman of the Board of Directors.
Cell Source Appoints Dr. Robert Negrin to Its Scientific Advisory Board
Marketwired - Mon Jul 06, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Robert S. Negrin, Director of the Bone and Marrow Transplantation Division and Professor of Medicine at Stanford University, has joined its Scientific Advisory Board.
Cell Source Appoints Dr. Steven Burakoff to Its Scientific Advisory Board
Marketwired - Mon Jun 29, 7:30AM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Steven Burakoff, Director of the Tisch Cancer Institute at Mount Sinai Medical Center and Professor of Cancer Medicine and Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, has joined its Scientific Advisory Board.
World Class Immunologist Dr. Herman Waldmann Joins Cell Source's Scientific Advisory Board
Marketwired - Wed Jun 17, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Herman Waldman, who served as Department Head and Professor Emeritus of Pathology at the Oxford Medical School and Clinical Director of Oxford's Therapeutic Antibody Centre, has joined the Cell Source Scientific Advisory Board.
Cell Source names Dr Terry Strom as SAB chair
M2 - Fri Jun 05, 4:52AM CDT
Biotechnology company Cell Source (OTCBB:CLCS) revealed on Thursday the addition of Dr Terry Strom as chairman of its Scientific Advisory Board (SAB).
Cell Source Appoints Dr. Terry Strom as Chairman of Its Scientific Advisory Board
Marketwired - Thu Jun 04, 10:22AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Terry Strom, Professor of Medicine and Surgery at Harvard Medical School and Director of The Transplant Institute at Beth Israel Deaconess Medical Center, has been retained to serve as Chairman of its Scientific Advisory Board.
